 |
|
Botulinum Toxin as a Biological Weapon
Medical and Public Health Management
Stephen S. Arnon, MD;
Robert Schechter, MD;
Thomas V. Inglesby, MD;
Donald A. Henderson, MD, MPH;
John G. Bartlett, MD;
Michael S. Ascher, MD;
Edward Eitzen, MD, MPH;
Anne D. Fine, MD;
Jerome Hauer, MPH;
Marcelle Layton, MD;
Scott Lillibridge, MD;
Michael T. Osterholm, PhD, MPH;
Tara O'Toole, MD, MPH;
Gerald Parker, PhD, DVM;
Trish M. Perl, MD, MSc;
Philip K. Russell, MD;
David L. Swerdlow, MD;
Kevin Tonat, PhD, MPH;
for the Working Group on Civilian Biodefense
JAMA. 2001;285:1059-1070.
ABSTRACT
| |
Objective The Working Group on Civilian Biodefense has developed consensus-based recommendations for measures to be taken by medical and public health professionals if botulinum toxin is used as a biological weapon against a civilian population.
Participants The working group included 23 representatives from academic, government, and private institutions with expertise in public health, emergency management, and clinical medicine.
Evidence The primary authors (S.S.A. and R.S.) searched OLDMEDLINE and MEDLINE (1960–March 1999) and their professional collections for literature concerning use of botulinum toxin as a bioweapon. The literature was reviewed, and opinions were sought from the working group and other experts on diagnosis and management of botulism. Additional MEDLINE searches were conducted through April 2000 during the review and revisions of the consensus statement.
Consensus Process The first draft of the working group's consensus statement was a synthesis of information obtained in the formal evidence-gathering process. The working group convened to review the first draft in May 1999. Working group members reviewed subsequent drafts and suggested additional revisions. The final statement incorporates all relevant evidence obtained in the literature search in conjunction with final consensus recommendations supported by all working group members.
Conclusions An aerosolized or foodborne botulinum toxin weapon would cause acute symmetric, descending flaccid paralysis with prominent bulbar palsies such as diplopia, dysarthria, dysphonia, and dysphagia that would typically present 12 to 72 hours after exposure. Effective response to a deliberate release of botulinum toxin will depend on timely clinical diagnosis, case reporting, and epidemiological investigation. Persons potentially exposed to botulinum toxin should be closely observed, and those with signs of botulism require prompt treatment with antitoxin and supportive care that may include assisted ventilation for weeks or months. Treatment with antitoxin should not be delayed for microbiological testing.
INTRODUCTION
This is the fourth article in a series entitled Medical and Public Health Management Following the Use of a Biological Weapon: Consensus Statements of The Working Group on Civilian Biodefense.1-3 This article is the only one in the series to feature a biological toxin rather than a replicating agent. Botulinum toxin poses a major bioweapon threat because of its extreme potency and lethality; its ease of production, transport, and misuse; and the need for prolonged intensive care among affected persons.4-5 An outbreak of botulism constitutes a medical emergency that requires prompt provision of botulinum antitoxin and, often, mechanical ventilation, and it constitutes a public health emergency that requires immediate intervention to prevent additional cases. Timely recognition of a botulism outbreak begins with an astute clinician who quickly notifies public health officials.
Botulinum toxin is the most poisonous substance known.6-7 A single gram of crystalline toxin, evenly dispersed and inhaled, would kill more than 1 million people, although technical factors would make such dissemination difficult. The basis of the phenomenal potency of botulinum toxin is enzymatic; the toxin is a zinc proteinase that cleaves 1 or more of the fusion proteins by which neuronal vesicles release acetylcholine into the neuromuscular junction.8
It is regrettable that botulinum toxin still needs to be considered as a bioweapon at the historic moment when it has become the first biological toxin to become licensed for treatment of human disease. In the United States, botulinum toxin is currently licensed for treatment of cervical torticollis, strabismus, and blepharospasm associated with dystonia. It is also used "off label" for a variety of more prevalent conditions that include migraine headache, chronic low back pain, stroke, traumatic brain injury, cerebral palsy, achalasia, and various dystonias.9-13
CONSENSUS METHODS
The working group included 23 representatives from academic, government, and private institutions with expertise in public health, emergency management, and clinical medicine. The 2 primary authors (S.S.A. and R.S.) conducted a literature search on use of botulinum toxin as a bioweapon. The OLDMEDLINE and MEDLINE databases were queried for all articles published between January 1960 and March 1999 that contained words referring to biological warfare (bioterrorism, biowarfare, terrorism, war, warfare, and weapon) in combination with terms related to Clostridium botulinum (bacillus, botulin, botulinal, botulinum, botulinus, botulism, clostridia, clostridial, and Clostridium). The articles identified in the databases were fully reviewed. In addition, published and unpublished articles, books, monographs, and special reports in the primary authors' collections were reviewed. Additional MEDLINE searches were conducted through April 2000 during the review and revisions of the consensus statement.
The first draft of the consensus statement was a synthesis of information obtained in the formal evidence-gathering process. Members of the working group provided written and oral comments about the first draft at their meeting in May 1999. Working group members then reviewed subsequent drafts and suggested additional revisions. The final statement incorporates all relevant evidence obtained in the literature search in conjunction with final consensus recommendations supported by all working group members.
The assessment and recommendations provided herein represent the best professional judgment of the working group based on currently available data and expertise. These conclusions and recommendations should be regularly reassessed as new information becomes available.
HISTORY OF CURRENT THREAT
Terrorists have already attempted to use botulinum toxin as a bioweapon. Aerosols were dispersed at multiple sites in downtown Tokyo, Japan, and at US military installations in Japan on at least 3 occasions between 1990 and 1995 by the Japanese cult Aum Shinriky . These attacks failed, apparently because of faulty microbiological technique, deficient aerosol-generating equipment, or internal sabotage. The perpetrators obtained their C botulinum from soil that they had collected in northern Japan.14-15
Development and use of botulinum toxin as a possible bioweapon began at least 60 years ago.16-17 The head of the Japanese biological warfare group (Unit 731) admitted to feeding cultures of C botulinum to prisoners with lethal effect during that country's occupation of Manchuria, which began in the 1930s.18 The US biological weapons program first produced botulinum toxin during World War II. Because of concerns that Germany had weaponized botulinum toxin, more than 1 million doses of botulinum toxoid vaccine were made for Allied troops preparing to invade Normandy on D-Day.19-20 The US biological weapons program was ended in 1969-1970 by executive orders of Richard M. Nixon, then president. Research pertaining to biowarfare use of botulinum toxin took place in other countries as well.21
Although the 1972 Biological and Toxin Weapons Convention prohibited offensive research and production of biological weapons, signatories Iraq and the Soviet Union subsequently produced botulinum toxin for use as a weapon.22-23 Botulinum toxin was 1 of several agents tested at the Soviet site Aralsk-7 on Vozrozhdeniye Island in the Aral Sea.23-24 A former senior scientist of the Russian civilian bioweapons program reported that the Soviets had attempted splicing the botulinum toxin gene from C botulinum into other bacteria.25 With the economic difficulties in Russia after the demise of the Soviet Union, some of the thousands of scientists formerly employed by its bioweapons program have been recruited by nations attempting to develop biological weapons.25-26 Four of the countries listed by the US government as "state sponsors of terrorism" (Iran, Iraq, North Korea, and Syria)27 have developed, or are believed to be developing, botulinum toxin as a weapon.28-29
After the 1991 Persian Gulf War, Iraq admitted to the United Nations inspection team to having produced 19 000 L of concentrated botulinum toxin, of which approximately 10 000 L were loaded into military weapons.22, 30 These 19 000 L of concentrated toxin are not fully accounted for and constitute approximately 3 times the amount needed to kill the entire current human population by inhalation. In 1990, Iraq deployed specially designed missiles with a 600-km range; 13 of these were filled with botulinum toxin, 10 with aflatoxin, and 2 with anthrax spores. Iraq also deployed special 400-lb (180-kg) bombs for immediate use; 100 bombs contained botulinum toxin, 50 contained anthrax spores, and 7 contained aflatoxin.22, 30 It is noteworthy that Iraq chose to weaponize more botulinum toxin than any other of its known biological agents.
Some contemporary analyses discount the potential of botulinum toxin as a bioweapon because of constraints in concentrating and stabilizing the toxin for aerosol dissemination. However, these analyses pertain to military uses of botulinum toxin to immobilize an opponent (William C. Patrick, unpublished data, 1998). In contrast, deliberate release of botulinum toxin in a civilian population would be able to cause substantial disruption and distress. For example, it is estimated that a point-source aerosol release of botulinum toxin could incapacitate or kill 10% of persons within 0.5 km downwind (William C. Patrick, unpublished data, 1998). In addition, terrorist use of botulinum toxin might be manifested as deliberate contamination of food. Misuse of toxin in this manner could produce either a large botulism outbreak from a single meal or episodic, widely separated outbreaks.31 In the United States, the Centers for Disease Control and Prevention (CDC) maintains a well-established surveillance system for human botulism based on clinician reporting that would promptly detect such events.32
MICROBIOLOGY AND VIRULENCE FACTORS
Clostridium botulinum is a spore-forming, obligate anaerobe whose natural habitat is soil, from which it can be isolated without undue difficulty. The species C botulinum consists of 4 genetically diverse groups that would not otherwise be designated as a single species except for their common characteristic of producing botulinum toxin.33-34 Botulinum toxin exists in 7 distinct antigenic types that have been assigned the letters A through G. The toxin types are defined by their absence of cross-neutralization (eg, anti-A antitoxin does not neutralize toxin types B-G). The toxin types also serve as convenient epidemiological markers. In addition to C botulinum, unique strains of Clostridium baratii and Clostridium butyricum have the capacity to produce botulinum toxin.35-37 Botulinum toxin is a simple dichain polypeptide that consists of a 100-kd "heavy" chain joined by a single disulfide bond to a 50-kd "light" chain; its 3-dimensional structure was recently resolved to 3.3 A.38 The toxin's light chain is a Zn++-containing endopeptidase that blocks acetylcholine-containing vesicles from fusing with the terminal membrane of the motor neuron, resulting in flaccid muscle paralysis (Figure 1).8
|
|
|
|
Figure 1. Mechanism of Action of Botulinum Toxin
A, Release of acetylcholine at the neuromuscular junction is mediated by the assembly of a synaptic fusion complex that allows the membrane of the synaptic vesicle containing acetylcholine to fuse with the neuronal cell membrane. The synaptic fusion complex is a set of SNARE proteins, which include synaptobrevin, SNAP-25, and syntaxin. After membrane fusion, acetylcholine is released into the synaptic cleft and then bound by receptors on the muscle cell. B, Botulinum toxin binds to the neuronal cell membrane at the nerve terminus and enters the neuron by endocytosis. The light chain of botulinum toxin cleaves specific sites on the SNARE proteins, preventing complete assembly of the synaptic fusion complex and thereby blocking acetylcholine release. Botulinum toxins types B, D, F, and G cleave synaptobrevin; types A, C, and E cleave SNAP-25; and type C cleaves syntaxin. Without acetylcholine release, the muscle is unable to contract. SNARE indicates soluble NSF-attachment protein receptor; NSF, N-ethylmaleimide-sensitive fusion protein; and SNAP-25, synaptosomal-associated protein of 25 kd.
|
|
|
The lethal dose of botulinum toxin for humans is not known but can be estimated from primate studies. By extrapolation, the lethal amounts of crystalline type A toxin for a 70-kg human would be approximately 0.09-0.15 µg intravenously or intramuscularly, 0.70-0.90 µg inhalationally, and 70 µg orally.10, 39-41 Therapeutic botulinum toxin represents an impractical bioterrorist weapon because a vial of the type A preparation currently licensed in the United States contains only about 0.3% of the estimated human lethal inhalational dose and 0.005% of the estimated lethal oral dose.
PATHOGENESIS AND CLINICAL MANIFESTATIONS
Three forms of naturally occurring human botulism exist: foodborne, wound, and intestinal (infant and adult). Fewer than 200 cases of all forms of botulism are reported annually in the United States.42 All forms of botulism result from absorption of botulinum toxin into the circulation from either a mucosal surface (gut, lung) or a wound. Botulinum toxin does not penetrate intact skin. Wound botulism and intestinal botulism are infectious diseases that result from production of botulinum toxin by C botulinum either in devitalized (ie, anaerobic) tissue43 or in the intestinal lumen,37 respectively. Neither would result from bioterrorist use of botulinum toxin.
A fourth, man-made form that results from aerosolized botulinum toxin is inhalational botulism. This mode of transmission has been demonstrated experimentally in primates,39 has been attempted by bioterrorists,14-15 and has been the intended outcome of at least 1 country's specially designed missiles and artillery shells.22, 30 Inhalational botulism has occurred accidentally in humans. A brief report from West Germany in 1962 described 3 veterinary personnel who were exposed to reaerosolized botulinum toxin while disposing of rabbits and guinea pigs whose fur was coated with aerosolized type A botulinum toxin. Type A botulinum toxin was detected in serum samples from all 3 affected individuals.21
Once botulinum toxin is absorbed, the bloodstream carries it to peripheral cholinergic synapses, principally, the neuromuscular junction, where it binds irreversibly. The toxin is then internalized and enzymatically blocks acetylcholine release (Figure 1). Accordingly, all forms of human botulism display virtually identical neurologic signs. However, the neurologic signs in naturally occurring foodborne botulism may be preceded by abdominal cramps, nausea, vomiting, or diarrhea.44 These gastrointestinal symptoms are thought to be caused by other bacterial metabolites also present in the food33 and may not occur if purified botulinum toxin is intentionally placed in foods or aerosols.
Botulism is an acute, afebrile, symmetric, descending flaccid paralysis that always begins in bulbar musculature. It is not possible to have botulism without having multiple cranial nerve palsies. Disease manifestations are similar regardless of botulinum toxin type. However, the extent and pace of paralysis may vary considerably among patients. Some patients may be mildly affected (Figure 2), while others may be so paralyzed that they appear comatose and require months of ventilatory support. The rapidity of onset and the severity of paralysis depend on the amount of toxin absorbed into the circulation. Recovery results from new motor axon twigs that sprout to reinnervate paralyzed muscle fibers, a process that, in adults, may take weeks or months to complete.45-46
|
|
|
|
Figure 2. Seventeen-Year-Old Patient With Mild Botulism
A, Patient at rest. Note bilateral mild ptosis, dilated pupils, disconjugate gaze, and symmetric facial muscles. B, Patient was requested to perform his maximum smile. Note absent periorbital smile creases, ptosis, disconjugate gaze, dilated pupils, and minimally asymmetric smile. As an indication of the extreme potency of botulinum toxin, the patient had 40 x 10-12g/mL of type A botulinum toxin in his serum (ie, 1.25 mouse units/mL) when these photographs were taken.
|
|
|
Patients with botulism typically present with difficulty seeing, speaking, and/or swallowing (Table 1 and Table 2). Prominent neurologic findings in all forms of botulism include ptosis, diplopia, blurred vision, often enlarged or sluggishly reactive pupils, dysarthria, dysphonia, and dysphagia.5, 44, 47-48 The mouth may appear dry and the pharynx injected because of peripheral parasympathetic cholinergic blockade. Sensory changes are not observed except for infrequent circumoral and peripheral paresthesias from hyperventilation as a patient becomes frightened by onset of paralysis.
|
|
|
|
Table 1. Symptoms and Signs of Foodborne Botulism, Types A and B*
|
|
|
|
|
|
|
Table 2. Symptoms and Signs of Inhalational Botulism in Order of Onset
|
|
|
As paralysis extends beyond bulbar musculature, loss of head control, hypotonia, and generalized weakness become prominent. Dysphagia and loss of the protective gag reflex may require intubation and, usually, mechanical ventilation. Deep tendon reflexes may be present initially but diminish or disappear in the ensuing days, and constipation may occur. In untreated persons, death results from airway obstruction (pharyngeal and upper airway muscle paralysis) and inadequate tidal volume (diaphragmatic and accessory respiratory muscle paralysis).
Because botulism is an intoxication, patients remain afebrile unless they also have acquired a secondary infection (eg, aspiration pneumonia). The toxin does not penetrate brain parenchyma, so patients are not confused or obtunded. However, they often appear lethargic and have communication difficulties because of bulbar palsies (Figure 2). Botulism may be recognized by its classic triad: (1) symmetric, descending flaccid paralysis with prominent bulbar palsies in (2) an afebrile patient with (3) a clear sensorium. The prominent bulbar palsies can be summarized in part as "4 Ds": diplopia, dysarthria, dysphonia, and dysphagia.
EPIDEMIOLOGY
Early recognition of outbreaks of botulism, whether natural or intentional, depends on heightened clinical suspicion. Aerosol dissemination may not be difficult to recognize because a large number of cases will share a common temporal and geographical exposure and will lack a common dietary exposure. However, identification of the common exposure site initially may be difficult because of the mobility of persons exposed during the incubation period. Botulism and botulinum toxin are not contagious and cannot be transmitted from person to person. In contrast, a microbe intentionally modified to produce botulinum toxin might be contagious.
No instances of waterborne botulism have ever been reported.42, 49-50 Although the potency of botulinum toxin has led to speculation that it might be used to contaminate a municipal water supply, this scenario is unlikely for at least 2 reasons.51 First, botulinum toxin is rapidly inactivated by standard potable water treatments (eg, chlorination, aeration).52 Second, because of the slow turnover time of large-capacity reservoirs, a comparably large (and technically difficult to produce and deliver) inoculum of botulinum toxin would be needed.53 In contrast with treated water, botulinum toxin may be stable for several days in untreated water or beverages.52, 54 Hence, such items should be investigated in a botulism outbreak if no other vehicle for toxin can be identified.
If food were deliberately used as a vehicle for the toxin, the outbreak would need to be distinguished from naturally occurring foodborne botulism. During the past 20 years, the epidemiology of foodborne botulism has expanded beyond its traditional association with home-preserved foods and now includes nonpreserved foods and public eating places,47 features that could make terrorist use of botulinum toxin more difficult to detect. Characteristics of outbreaks of botulism include:
Incubation Period
The rapidity of onset and severity of botulism depend on the rate and amount of toxin absorption. Symptoms of foodborne botulism may begin as early as 2 hours or as long as 8 days after ingestion of toxin.55-56 Typically, cases present 12 to 72 hours after the implicated meal. In 1 large foodborne outbreak, new cases presented during the ensuing 3 days at a fairly even rate before decreasing (Figure 3).57 The time to onset of inhalational botulism cannot be stated with certainty because so few cases are known. Monkeys showed signs of botulism 12 to 80 hours after aerosol exposure to 4 to 7 multiples of the monkey median lethal dose.39 The 3 known human cases of inhalational botulism had onset of symptoms approximately 72 hours after exposure to an unknown but probably small amount of reaerosolized toxin.21
|
|
|
|
Figure 3. Fifty-Nine Cases of Botulism, by Interval Between Eating at a Restaurant and Onset of First Neurologic Symptom— Michigan, 1977
Reproduced from Terranova et al57 with permission of Oxford University Press.
|
|
|
Age and Sex
Persons of all ages are potentially susceptible to botulism. There are no sex differences in susceptibility.
Agent and Vehicles
Botulinum toxin in solution is colorless, odorless, and, as far as is known, tasteless. The toxin is readily inactivated by heat ( 85°C for 5 minutes).33-34,52 Thus, foodborne botulism is always transmitted by foods that are not heated, or not heated thoroughly, before eating. Almost every type of food has been associated with outbreaks of botulism, but the most commonly implicated foods in the United States are vegetables, particularly "low-acid" (ie, higher pH) vegetables such as beans, peppers, carrots, and corn.42, 50, 58
A novel epidemiological development is the occurrence of foodborne botulism after eating various nonpreserved foods in restaurants or delicatessens. Foil-wrapped baked potatoes are now known to be capable of causing restaurant-associated foodborne botulism59 when held at room temperature after baking and then served plain,60 as potato salad,61-62 or as a Mediterranean-style dip.59 Other outbreaks that originated in restaurants resulted from contaminated condiments such as sautéed onions,63 garlic in oil,64 and commercial cheese sauce.65 Additional examples of notable commercial foods that have caused botulism outbreaks include inadequately eviscerated fish,66 yogurt,67 cream cheese,68 and jarred peanuts.69
Incidence and Outbreak Size
Naturally occurring foodborne botulism is a rare disease. Approximately 9 outbreaks of foodborne botulism and a median of 24 cases occur annually in the United States.42, 47 The mean outbreak size has remained constant over the years at approximately 2.5 cases per outbreak. The largest outbreak of foodborne botulism in the United States in the last 100 years occurred in Michigan in 1977; 59 cases resulted from eating home-preserved jalapeño peppers at a restaurant.57 However, only 45 of the 59 patients had clinically evident weakness and hypotonia.
Toxin Types
Of the 135 foodborne outbreaks in the 16 years from 1980 to 1996 in the United States, the toxin types represented were: type A, 54.1%; type B, 14.8%; type E, 26.7%; type F, 1.5%; and unknown, 3.0%.42 Type F foodborne outbreaks are rare in the United States; a 1962 outbreak resulted from homemade venison jerky,70 while other type F cases actually may have had intestinal botulism.71 Toxin types C and D cause botulism in wildlife and domestic animals but have not caused human foodborne disease. However, humans are thought to be susceptible to these toxin types because they have caused botulism in primates when ingested.72-74 Toxin type G is produced by a bacteria species discovered in South American soil in 1969 that has never caused recognized foodborne botulism.75 Aerosol challenge studies in monkeys have established the susceptibility of primates to inhaled botulinum toxin types C, D, and G.48
Distribution
Although outbreaks of foodborne botulism have occurred in almost all states, more than half (53.8%) of the US outbreaks have occurred in just 5 western states (California, Washington, Oregon, Colorado, and Alaska). East of the Mississippi River, 60% of the foodborne outbreaks have resulted from type B toxin, while west of the Mississippi River, 85% have resulted from type A toxin. In the 46 years between 1950 and 1996, 20 states, mainly in the eastern United States, did not report any type A botulism outbreaks, while 24 states, mostly in the western United States, did not report any type B outbreaks.42 In Canada and Alaska, most foodborne outbreaks resulted from type E toxin associated with native Inuit and Eskimo foods.50, 76
Bioterrorism Considerations
Any outbreak of botulism should bring to mind the possibility of bioterrorism, but certain features would be particularly suggestive (BOX 1). The availability and speed of air transportation mandate that a careful travel and activity history, as well as a careful dietary history, be taken. Patients should also be asked whether they know of other persons with similar symptoms. Absence of a common dietary exposure among temporally clustered patients should suggest the possibility of inhalational botulism.
| Box 1. Features of an Outbreak That Would Suggest a Deliberate Release of Botulinum Toxin
Outbreak of a large number of cases of acute flaccid paralysis with prominent bulbar palsies
Outbreak with an unusual botulinum toxin type (ie, type C, D, F, or G, or type E toxin not acquired from an aquatic food)
Outbreak with a common geographic factor among cases (eg, airport, work location) but without a common dietary exposure (ie, features suggestive of an aerosol attack)
Multiple simultaneous outbreaks with no common source
Note: A careful travel and activity history, as well as dietary history, should be taken in any suspected botulism outbreak. Patients should also be asked if they know of other persons with similar symptoms.
RETURN TO TEXT |
|
DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS
Clinical diagnosis of botulism is confirmed by specialized laboratory testing that often requires days to complete. Routine laboratory test results are usually unremarkable. Therefore, clinical diagnosis is the foundation for early recognition of and response to a bioterrorist attack with botulinum toxin.
Any case of suspected botulism represents a potential public health emergency because of the possibility that a contaminated food remains available to others or that botulinum toxin has been deliberately released. In these settings, prompt intervention by civil authorities is needed to prevent additional cases. Consequently, clinicians caring for patients with suspected botulism should notify their local public health department and hospital epidemiologist immediately to coordinate shipment of therapeutic antitoxin, laboratory diagnostic testing, and epidemiological investigation (BOX 2). In most jurisdictions of the United States, botulism suspected on clinical grounds alone by law must be reported immediately by telephone to local public health authorities. The attending clinician needs to be both prompt and persistent in accomplishing this notification.
| Box 2. Clinicians Caring for Patients With Suspected Botulism Should Immediately Contact Their:
(1) Hospital epidemiologist or infection control practitioner
and
(2) Local and state health departments
Consult your local telephone operator; the telephone directory under "government listings," or the Internet at: http://www.cdc.gov/other.htm#states or http://www.astho.org/state.html
If the local and state health departments are unavailable, contact the Centers for Disease Control and Prevention: (404) 639-2206; (404) 639-2888 [after hours].
RETURN TO TEXT |
|
Differential Diagnosis
Botulism is frequently misdiagnosed, most often as a polyradiculoneuropathy (Guillain-Barré or Miller-Fisher syndrome), myasthenia gravis, or a disease of the central nervous system (Table 3). In the United States, botulism is more likely than Guillain-Barré syndrome, intoxication, or poliomyelitis to cause a cluster of cases of acute flaccid paralysis. Botulism differs from other flaccid paralyses in its prominent cranial nerve palsies disproportionate to milder weakness and hypotonia below the neck, in its symmetry, and in its absence of sensory nerve damage.
|
|
|
|
Table 3. Selected Mimics and Misdiagnoses of Botulism*
|
|
|
A large, unintentional outbreak of foodborne botulism caused by a restaurant condiment in Canada provides a cautionary lesson about the potential difficulties in recognizing a covert, intentional contamination of food.64 During a 6-week period in which the condiment was served, 28 persons in 2 countries became ill, but all were misdiagnosed (Table 3). The 28 were identified retrospectively only after correct diagnoses in a mother and her 2 daughters who had returned to their home more than 2000 miles away from the restaurant. Four (14%) of the cases had been misdiagnosed as having psychiatric disease, including "factitious" symptoms. It is possible that hysterical paralysis might occur as a conversion reaction in the anxiety that would follow a deliberate release of botulinum toxin.
Diagnostic Testing
At present, laboratory diagnostic testing for botulism in the United States is available only at the CDC and approximately 20 state and municipal public health laboratories.42 The laboratory should be consulted prospectively about specimen collection and processing. Samples used in diagnosis of botulism include serum (30 mL of blood in "tiger"-top or red-top tubes from adults, less from children), stool, gastric aspirate, and, if available, vomitus and suspect foods. Serum samples must be obtained before therapy with antitoxin, which nullifies the diagnostic mouse bioassay. An enema may be required to obtain an adequate fecal sample if the patient is constipated. Sterile water should be used for this procedure because saline enema solution can confound the mouse bioassay. Gastric aspirates and, perhaps, stool may be useful for detecting inhaled aerosolized botulinum toxin released in a bioterrorist attack.77 A list of the patient's medications should accompany the diagnostic samples because anticholinesterases, such as pyridostigmine bromide, and other medicines that are toxic to mice can be dialyzed from samples before testing. All samples should be kept refrigerated after collection.
The standard laboratory diagnostic test for clinical specimens and foods i |
